Evidence map›Paper›PMID 38279565›Full record

ArticleMolecular oncology2024

ASPM stabilizes the NOTCH intracellular domain 1 and promotes oncogenesis by blocking FBXW7 binding in hepatocellular carcinoma cells.

Tze-Sian Chan, Li-Hsin Cheng, Chung-Chi Hsu, Pei-Ming Yang, Tai-Yan Liao, Hsiao-Yen Hsieh, Pei-Chun Lin, Wei-Chun HuangFu, Chih-Pin Chuu, Kelvin K Tsai

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Identification of prognosis-related key genes in hepatocellular carcinoma based on bioinformatics analysis.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Tze-Sian ChanLaboratory of Advanced Molecular Therapeutics, Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taiwan.
Li-Hsin ChengLaboratory of Advanced Molecular Therapeutics, Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taiwan.
Chung-Chi HsuSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung City, Taiwan.
Pei-Ming YangMaster Program in Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taiwan.ORCID 0000-0002-4004-2518
Tai-Yan LiaoLaboratory of Advanced Molecular Therapeutics, Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taiwan.
Hsiao-Yen HsiehLaboratory of Advanced Molecular Therapeutics, Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taiwan.
Pei-Chun LinLaboratory of Advanced Molecular Therapeutics, Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taiwan.
Wei-Chun HuangFuMaster Program in Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taiwan.
Chih-Pin ChuuInstitute of Cellular and System Medicine, National Health Research Institutes, Miaoli, Taiwan.ORCID 0000-0001-7206-7923
Kelvin K TsaiLaboratory of Advanced Molecular Therapeutics, Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taiwan.ORCID 0000-0002-1612-2868
Taipei Medical University · TWI-Shou University · TWNational Health Research Institutes · TWTaipei Medical University Hospital · TWWan Fang Hospital · TW

Funding

National Science and Technology Council, Taiwan (R.O.C.) MOST 108-2314-B-038-105National Science and Technology Council, Taiwan (R.O.C.) MOST 109-2314-B-038-130National Science and Technology Council, Taiwan (R.O.C.) MOST 111-2314-B-038-075National Science and Technology Council, Taiwan (R.O.C.) MOST 111-2320-B-038-021National Science and Technology Council, Taiwan (R.O.C.) MOST 111-2327-B-038-001National Science and Technology Council, Taiwan (R.O.C.) NSTC112-2823-8-038-004Taipei Medical University 109-TMU-WFH-05Taipei Medical University DP2-107-21121-C-04Taipei Medical University DP2-TMU-112-0-12Taipei Medical University TMU106-AE1-B31Wan Fang Hospital, Taipei Medical University 112-WF-SWF-01
6 · The paper itself

Abstract

Notch signaling is aberrantly activated in approximately 30% of hepatocellular carcinoma (HCC), significantly contributing to tumorigenesis and disease progression. Expression of the major Notch receptor, NOTCH1, is upregulated in HCC cells and correlates with advanced disease stages, although the molecular mechanisms underlying its overexpression remain unclear. Here, we report that expression of the intracellular domain of NOTCH1 (NICD1) is upregulated in HCC cells due to antagonism between the E3-ubiquitin ligase F-box/WD repeat-containing protein 7 (FBXW7) and the large scaffold protein abnormal spindle-like microcephaly-associated protein (ASPM) isoform 1 (ASPM-i1). Mechanistically, FBXW7-mediated polyubiquitination and the subsequent proteasomal degradation of NICD1 are hampered by the interaction of NICD1 with ASPM-i1, thereby stabilizing NICD1 and rendering HCC cells responsive to stimulation by Notch ligands. Consistently, downregulating ASPM-i1 expression reduced the protein abundance of NICD1 but not its FBXW7-binding-deficient mutant. Reinforcing the oncogenic function of this regulatory module, the forced expression of NICD1 significantly restored the tumorigenic potential of ASPM-i1-deficient HCC cells. Echoing these findings, NICD1 was found to be strongly co-expressed with ASPM-i1 in cancer cells in human HCC tissues (P < 0.001). In conclusion, our study identifies a novel Notch signaling regulatory mechanism mediated by protein-protein interaction between NICD1, FBXW7, and ASPM-i1 in HCC cells, representing a targetable vulnerability in human HCC.

Indexed as

Carcinoma, HepatocellularF-Box ProteinsLiver NeoplasmsCell Line, TumorF-Box-WD Repeat-Containing Protein 7HumansNerve Tissue ProteinsReceptor, Notch1ASPM protein, humanF-Box ProteinsF-Box-WD Repeat-Containing Protein 7FBXW7 protein, humanNerve Tissue ProteinsNOTCH1 protein, humanReceptor, Notch1ASPMFBXW7hepatocellular carcinomaNOTCH1Notch signalingtumorigenesis

Identifiers

PMID38279565
PMCPMC10920086
OpenAlexW4391282231

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.